A Closer Look At The US Pricing Pushback
This article was originally published in Scrip
Executive Summary
Critics of high prescription drug prices are making headlines in the US, and politicians on the presidential campaign trail and on Capitol Hill are talking about government-imposed price controls. But the real news may be unfolding behind the scenes in the private health insurance market, as Cathy Kelly finds out.
You may also be interested in...
Cigna’s Bradbury Talks PCSK9 Contracts And Value Versus Volume
Amgen and Sanofi/Regeneron will pay deeper discounts if patients taking Repatha and Praluent don’t experience similar levels of LDL-cholesterol lowering as was seen in clinical trials.
Medicare Walks Back Proposed Payment Policy For 505(b)(2) Physician Administered Drugs
CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’
US Payers Rate ICER Assessment Updates Using Real World Data As Potentially ‘High Impact’
ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.
Need a specific report? 1000+ reports available
Buy Reports